NIKKEI 225
38,293.42 +113.96 (+0.30%) HANG SENG
19,097.17 -17.89 (-0.09%) CRUDE OIL
79.23 +0.11 (+0.14%) GOLD FUTURES
2,349.70 +6.70 (+0.29%) DOW
39,431.51 -81.29 (-0.21%) Bitcoin GBP
49,301.53 +659.80 (+1.36%)
NVO Jul 2024 135.000 call
| Previous close | 5.50 |
| Open | 4.55 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 135.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.55 - 6.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
BenzingaNovo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Monday, Novo Nordisk A/S (NYSE:NVO) released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in hemophilia A patients 12 years or older with or without inhibitors. Read Next: Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro. The trial achieved its co-primary endpoints by demonstrating a statistically significant a
